Sobi Seeks EU Expansion for Tryngolza in Severe Hypertriglyceridemia

Event summary

  • Sobi has submitted an application to the EMA for an expanded indication of Tryngolza (olezarsen) to treat adult patients with severe hypertriglyceridemia (sHTG) ≥880 mg/dL.
  • The application is supported by Phase 3 CORE and CORE2 trial data published in the New England Journal of Medicine in 2025, demonstrating a reduction in acute pancreatitis risk.
  • Tryngolza is already approved in the EU (since September 2025) for familial chylomicronemia syndrome (FCS).
  • Sobi commercializes Tryngolza ex-U.S. except Canada and China, under a license agreement with Ionis Pharmaceuticals.
  • Approximately 700,000 people in the EU5 have triglyceride levels ≥880 mg/dL, representing a significant unmet need.

The big picture

Sobi’s pursuit of this expanded indication for Tryngolza underscores the growing focus on addressing severe hypertriglyceridemia, a condition with significant morbidity and mortality. The company’s reliance on a licensing agreement with Ionis Pharmaceuticals creates a dependency that could impact future pricing and development decisions. The success of this application will be a key indicator of Sobi’s ability to expand its rare disease portfolio and drive revenue growth, given the company’s SEK 28 billion revenue in 2025.

What we're watching

Regulatory Approval
The EMA’s decision on the expanded indication will be critical for Sobi’s revenue projections and market penetration within the sHTG patient population.
Commercial Execution
Sobi’s ability to effectively market and distribute Tryngolza to the expanded patient pool, particularly given the need for specialized treatment and monitoring, will determine the success of this expansion.
Competitive Landscape
The emergence of alternative therapies or competing approaches to managing sHTG could erode Tryngolza’s market share and pricing power, despite its current first-mover advantage.